Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06233942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
April 12, 2024
Completion date
May 15, 2028
Enrollment
308 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor